BriaCell Therapeutics Corp. (TSE:BCT – Get Free Report) shares fell 20.9% on Friday . The stock traded as low as C$4.27 and last traded at C$4.39. 93,500 shares traded hands during trading, an increase of 283% from the average session volume of 24,408 shares. The stock had previously closed at C$5.55.
BriaCell Therapeutics Trading Down 25.6%
The company has a market cap of C$29.94 million, a price-to-earnings ratio of -0.29 and a beta of 1.95. The stock’s fifty day simple moving average is C$5.66 and its 200 day simple moving average is C$8.70.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers.
Recommended Stories
- Five stocks we like better than BriaCell Therapeutics
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
